New research has identified a potential, if small, added risk of smell and taste disturbances linked to GLP-1 use.

New research finds that rates of GLP-1 use and misuse are shockingly high among people with a history of eating disorders.

Weight loss jabs like Mounjaro and Ozempic have been linked with a nearly 50 per cent increased risk of taste and smell disturbances, a study has found.